Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer.
about
Immunotherapy in the treatment of non-small cell lung cancerBiomarkers in early-stage non-small-cell lung cancer: current concepts and future directions.Role of CTLA4 in the proliferation and survival of chronic lymphocytic leukemia.Modelling the spatial heterogeneity and molecular correlates of lymphocytic infiltration in triple-negative breast cancer.PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironmentEffect of cytotoxic T-lymphocyte antigen-4, TNF-alpha polymorphisms on osteosarcoma: evidences from a meta-analysis.The prognostic value of cytotoxic T-lymphocyte antigen 4 in cancers: a systematic review and meta-analysis.Polymorphisms of co-inhibitory molecules (CTLA-4/PD-1/PD-L1) and the risk of non-small cell lung cancer in a Chinese populationExpression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma.Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma.Ctla-4 expression and polymorphisms in lung tissue of patients with diagnosed non-small-cell lung cancer.Genome-wide DNA methylation profile identified a unique set of differentially methylated immune genes in oral squamous cell carcinoma patients in India.Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes groupPrognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics.Challenges and opportunities for cancer vaccines in the current NSCLC clinical scenario.Role of immunotherapy in the treatment of advanced non-small-cell lung cancer.Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy.Overcoming tumor-mediated immunosuppression.The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcomeLow immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?Targeting the immune system to treat lung cancer: rationale and clinical experience.Regulatory T cells and potential inmmunotherapeutic targets in lung cancer.Combination radiotherapy and cantharidin inhibits lung cancer growth through altering tumor infiltrating lymphocytes.ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer.Lung Cancer Staging and Prognosis.Immune checkpoints and their inhibition in cancer and infectious diseases.Targeting PD-1/PD-L1 in lung cancer: current perspectives.Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients.Clinical Implications of Cytotoxic T Lymphocyte Antigen-4 Expression on Tumor Cells and Tumor-Infiltrating Lymphocytes in Extrahepatic Bile Duct Cancer Patients Undergoing Surgery Plus Adjuvant Chemoradiotherapy.The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production.CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor.PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed.CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases.Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes.Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.Immune cell landscape in therapy-naïve squamous cell and adenocarcinomas of the lung.High CTLA-4 expression correlates with poor prognosis in thymoma patients.Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.Cytotoxic T lymphocyte associated antigen 4 expression predicts poor prognosis in luminal B HER2-negative breast cancer.
P2860
Q27000382-B08ADC54-56BB-48EE-A216-12422265F65DQ34623884-C2CADB3B-640C-4188-9F9C-C2913F8AA2DFQ34925487-4795B760-E727-4288-BE6F-861FAB49C22DQ35009369-433DD088-5C3B-4968-BBBE-BF2E9E3DF2F3Q35044301-08328F8A-7BA8-4016-944F-2F3ACED4C331Q35079792-82277AA3-C67C-45FD-A0CE-41104FC7B382Q36283876-CA4907FF-5F16-49F2-8437-7DA2BA08B42CQ36318092-8DA546D5-3599-4E44-B5EB-BF6224B34DBFQ36333164-81083DF4-0759-415A-9B75-1BD38B8FB9D9Q37012537-F3E8AFD9-B3A3-46BB-8222-810F59D301EAQ37022378-D6A6B20A-3021-464F-8F6F-263809D91E94Q37044252-12C9246B-8A7F-4BC3-A97B-0F89593F94DFQ37624648-C97C4C07-79B1-42AE-889A-C9853E790E0DQ37697018-3C4AB34F-7EBD-41CC-8ED3-3A6DF97F56E4Q37745995-549F12F8-DC7A-473E-ABEB-94A201A4CE2CQ38143201-66778369-2B9A-451D-8610-E66E9F5DBF6EQ38170384-52AF70A5-FCD9-407B-B9C3-23ABEFF7E3AEQ38202161-229962CA-A58C-49F8-875A-1EA568BFAA2BQ38262255-B02F0D1F-1917-4838-BAA1-CFE5F5838B27Q38264982-9DF46E42-9A19-43D0-9F46-079BAABC148EQ38366141-4E8D5D3A-051F-4AA3-8594-55A80AD5912DQ38397629-FB22573A-7E3B-43C9-A216-B6C4558AF223Q38473314-F9F9AFB3-D98B-420E-AD59-41CEF3E3C08FQ38684656-48590556-8FD4-41FD-B021-FE4EF385355AQ38733611-43BEFC05-192D-4145-A9A7-F5C58C04A641Q38830349-39A96B25-5F1E-49EE-A506-BDD2701DB20DQ38845026-A994AC15-8BC2-41FC-9A8B-4FC27AAE9913Q38956294-9DEEDD1B-2DD4-4A64-AD23-86DB9697A47EQ38961444-63663F0A-DF93-4A89-B807-44AFBCB977E1Q39022564-1CFEA663-643C-45AB-8AD1-FB2E3A3CA8CDQ39157852-7D128BC7-742E-4025-9C8A-3C63E6BCC849Q39748066-AE571B80-A0ED-4D29-9AED-196EB1EBEEC6Q42371630-5B1F680B-8A33-4076-8DDE-0E4D1A705283Q42683596-592B8826-BD14-40B7-AB53-EAAD17E4EDF0Q50345931-AE62EC80-FA71-452C-8E10-70F2C94BA377Q52577907-7B2B8EAC-996F-42A9-929D-5256A3476B10Q52665504-C49C9B83-853E-4D63-A626-7F7FDAF7AB4CQ54943060-C9FB1BA2-96A6-4914-A489-6D3CEABF4C53Q54960920-E7607BBC-80C5-4CF0-849B-FAA953C1569CQ55296766-BF360A6E-1229-438E-A5F8-7C387CE71614
P2860
Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Evaluation of CTLA-4 expressio ...... th non-small cell lung cancer.
@en
Evaluation of CTLA-4 expressio ...... th non-small cell lung cancer.
@nl
type
label
Evaluation of CTLA-4 expressio ...... th non-small cell lung cancer.
@en
Evaluation of CTLA-4 expressio ...... th non-small cell lung cancer.
@nl
prefLabel
Evaluation of CTLA-4 expressio ...... th non-small cell lung cancer.
@en
Evaluation of CTLA-4 expressio ...... th non-small cell lung cancer.
@nl
P2093
P2860
P50
P1476
Evaluation of CTLA-4 expressio ...... ith non-small cell lung cancer
@en
P2093
Anna Morabito
Edoardo Margallo
Erika Rijavec
Giovanni Battista Ratto
Marco Mora
Maria Giovanna Dal Bello
Mauro Truini
Sandra Salvi
Simona Boccardo
Stefania Laurent
P2860
P2888
P304
P356
10.1007/S00262-012-1211-Y
P577
2012-02-09T00:00:00Z